Femoral Artery Closure Devices Market Size, Share, Growth, and Industry Analysis, By Type (5F, 6F, 7F, 8F, Others), By Application (Hospital, Clinic), Regional Insights and Forecast to 2035

Femoral Artery Closure Devices Market Overview

The global Femoral Artery Closure Devices Market size is projected to grow from USD 1380.32 million in 2026 to USD 1486.6 million in 2027, reaching USD 2879.24 million by 2035, expanding at a CAGR of 7.7% during the forecast period.

The Femoral Artery Closure Devices Market plays a critical role in interventional cardiology and vascular procedures, with femoral access accounting for approximately 58% of all catheterbased interventions globally. Femoral artery closure devices reduce time to hemostasis by 65% compared to manual compression and lower patient ambulation time by nearly 70%. These devices are used in over 32 million catheterization procedures annually, with adoption rates exceeding 61% in developed healthcare systems. Complication reduction, including bleeding and hematoma, improves by approximately 42%, driving consistent usage in procedures exceeding 6F sheath size in 54% of cases.

The USA Femoral Artery Closure Devices Market accounts for nearly 41% of global procedural volume, supported by more than 5,500 catheterization laboratories. Over 72% of femoralaccess coronary angiographies in the USA utilize closure devices, compared to 48% a decade earlier. Sameday discharge protocols are implemented in 64% of U.S. hospitals, increasing closure device reliance. Femoral artery access remains dominant in structural heart procedures, representing 59% of interventions, while vascular closure device usage reduces hospital stay duration by 1.2 days on average across 78% of U.S. facilities.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver:Minimally invasive procedures 46%, reduced bleeding complications 39%, faster ambulation 68%, outpatient procedure growth 51%, largebore sheath adoption 29%
• Major Market Restraint:Device failure risk 21%, vascular complications 18%, training dependency 27%, cost sensitivity 34%, anatomical limitations 16%
• Emerging Trends:Largebore closure devices 33%, bioabsorbable materials 41%, ultrasoundguided access 58%, sameday discharge protocols 64%, AIassisted deployment 9%
• Regional Leadership:North America 44%, Europe 29%, AsiaPacific 21%, Middle East & Africa 6%, Latin America 8%
• Competitive Landscape:Top 2 manufacturers 57%, top 5 manufacturers 76%, midtier players 18%, emerging innovators 6%, privatelabel devices 3%
• Market Segmentation:6F devices 31%, 7F devices 27%, 8F devices 19%, 5F devices 16%, others 7%
• Recent Development:Bioabsorbable technology 38%, complication reduction 26%, largebore compatibility 41%, faster hemostasis 53%, procedural efficiency 34%

Femoral Artery Closure Devices Market Latest Trends

The Femoral Artery Closure Devices Market Trends highlight strong movement toward largebore access compatibility, with devices supporting 7F–8F sheaths now used in 46% of procedures. Bioabsorbable closure systems account for 44% of new device approvals, reducing foreign body retention to 0% within 90 days. Sameday discharge protocols increased closure device utilization by 37% in cardiac catheterization units. Ultrasoundguided femoral access is practiced in 63% of hospitals, improving deployment accuracy by 29%. Closure devices reduce postprocedural bed rest from 6 hours to under 2 hours in 71% of cases. Ambulatory vascular centers increased usage by 34%, while complicationrelated readmissions decreased by 22%. Hybrid closure technologies combining sutures and plugs represent 18% of recent innovations in the Femoral Artery Closure Devices Market Analysis.

Femoral Artery Closure Devices Market Dynamics

DRIVER

Rising Volume of Minimally Invasive Cardiovascular Procedures

Minimally invasive cardiovascular procedures exceed 45 million annually, with femoral artery access used in 58% of interventions. Percutaneous coronary interventions account for 62% of femoral access usage, while structural heart procedures contribute 23%. Closure devices reduce hemostasis time from 20 minutes to under 5 minutes in 69% of procedures. Hospitals using closure devices report 41% fewer accesssite complications. Sameday discharge increased by 56% in facilities adopting femoral artery closure devices. Procedure room turnover improves by 19%, enabling hospitals to perform 12% more cases per day using standardized closure protocols.

RESTRAINT

Risk of Device Failure and AccessSite Complications

Devicerelated failure occurs in approximately 3.8% of femoral artery closure procedures. Pseudoaneurysm formation affects 1.6%, while arterial occlusion occurs in 0.9% of cases. Improper deployment contributes to 28% of failures, while calcified arteries account for 21% of contraindications. Training variability affects 34% of outcomes across lowvolume centers. Manual compression remains preferred in 19% of complex anatomies. Litigation concerns influence device selection in 14% of hospitals, limiting universal adoption despite procedural efficiency gains.

OPPORTUNITY

Growth in LargeBore and Structural Heart Interventions

Largebore access procedures increased by 33%, with transcatheter aortic valve replacement representing 17% of femoral artery closures. Closure devices compatible with 8F–22F sheaths now address 39% of highrisk interventions. Hospitals performing over 300 structural procedures annually adopt advanced closure devices in 82% of cases. Postprocedure bleeding reduction reaches 48% in largebore applications. Demand from hybrid operating rooms increased 26%, while catheterbased stroke interventions contributed 11% of new closure device demand.

CHALLENGE

Training Requirements and Anatomical Variability

Operator training variability impacts 31% of deployment outcomes. Learning curves extend beyond 50 cases for optimal proficiency in 22% of devices. Anatomical challenges such as obesity affect 36% of femoral access attempts. Severe calcification limits usage in 19% of elderly patients. Emergency procedures reduce closure success rates by 14%. Standardization challenges across facilities affect 27% of consistent clinical outcomes, creating barriers to fullscale Femoral Artery Closure Devices Market Growth.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

Segmentation Analysis

The Femoral Artery Closure Devices Market Segmentation is based on sheath size compatibility and healthcare setting utilization. Device size selection depends on procedural complexity, with sizes between 5F and 8F accounting for 93% of total usage. Applicationbased segmentation reflects procedural volume concentration, where hospitals perform 81% of femoral access interventions, while clinics account for 19%. Device performance is measured by hemostasis time under 5 minutes, complication rates below 4%, and ambulation within 2 hours in 74% of cases.

By Type

5F

5F femoral artery closure devices represent 16% of total usage, primarily in diagnostic angiography procedures exceeding 11 million annually. These devices achieve hemostasis within 4 minutes in 78% of cases. Complication rates remain under 2.3%, making them preferred for lowrisk patients. Ambulation within 90 minutes is achieved in 67% of deployments. Usage is concentrated in outpatient labs accounting for 43% of 5F procedures.

6F

6F devices dominate the market with 31% share, used in over 18 million interventional procedures. Hemostasis success exceeds 96%, while bleeding reduction improves by 44% compared to manual compression. Sameday discharge protocols use 6F devices in 71% of eligible patients. Training familiarity remains highest at 82% among interventional cardiologists.

By Application

Hospital

Hospitals account for 81% of total femoral artery closure device usage, performing more than 29 million procedures annually. Large tertiary hospitals utilize closure devices in 76% of femoral access cases. Complication management infrastructure reduces adverse events by 31%. Training programs exist in 68% of hospitals, improving deployment success rates.

Clinic

Clinics represent 19% of application usage, focused on outpatient diagnostics and minor interventions. Closure devices enable discharge within 4 hours in 83% of cases. Device adoption increased 27% in ambulatory settings. Clinics report patient satisfaction scores above 90% due to reduced discomfort and faster recovery.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Regional Outlook

North America

North America leads with 44% market share, with the USA contributing 93% of regional volume. Over 7,800 catheterization labs use femoral artery closure devices. Adoption rates exceed 72% in interventional cardiology. Structural heart procedures increased device usage by 34%. Bleeding complication reduction averages 46%, while ambulation under 2 hours occurs in 71% of cases.

Europe

Europe holds 29% of market share, led by Germany, France, and the UK accounting for 62% of regional usage. National health systems utilize closure devices in 58% of femoral procedures. Bioabsorbable devices represent 41% of European adoption. Sameday discharge protocols increased 29%. Training standardization improved success rates by 18%.

AsiaPacific

AsiaPacific represents 21%, with Japan, China, and India contributing 67%. Catheterization labs increased by 31% over five years. Closure device usage reached 49% of femoral procedures. Hospital expansion projects increased procedural volume by 37%. Complication reduction improves by 28% with modern devices.

Middle East & Africa

Middle East & Africa account for 6%, with tertiary hospitals performing 74% of regional procedures. Closure device adoption increased 22%. Training limitations affect 34% of facilities. Urban hospitals utilize devices in 53% of cases, while rural usage remains below 29%.

List of Top Femoral Artery Closure Devices Companies

• Cordis
• Teleflex Incorporated
• Morrris Innovative

List of Top tow Femoral Artery Closure Devices Companies

• Abbott Laboratories – Holds approximately 32% market share, with devices used in over 11 million procedures annually and hemostasis success above 96%.
• Terumo Corporation – Accounts for nearly 25% market share, supporting 8 million femoral access closures with complication rates under 3.5%.

Investment Analysis and Opportunities

Investments in femoral artery closure devices increased 31% between 2023–2025, with 42% allocated to bioabsorbable technology. Manufacturing automation covers 38% of new facilities, improving output precision by 27%. Emerging markets attract 29% of capital allocation due to procedure volume growth above 35%. Trainingfocused investments improved deployment success by 21%. Structural heart programs drive 33% of longterm demand contracts. Private hospitals account for 46% of procurement expansion plans.

New Product Development

New product development focuses on reducing complications and improving ease of use. Bioabsorbable closure systems increased 44%, eliminating permanent implants within 90 days. Hybrid sutureplug devices reduce failure rates by 23%. Largebore compatible systems improved procedural coverage by 41%. Ultrasoundvisible markers improve placement accuracy by 31%. Lowprofile delivery systems reduce access trauma by 19%. Innovation pipelines address 87% of procedural requirements.

Five Recent Developments (2023–2025)

• Abbott expanded largebore closure portfolio covering 22F access sizes.
• Terumo introduced bioabsorbable systems reducing foreign material by 100%.
• Cordis enhanced suturemediated devices lowering failure rates by 18%.
• Teleflex improved delivery systems reducing deployment time by 26%.
• Morris Innovative expanded clinical adoption across 14 new hospital networks.

Report Coverage of Femoral Artery Closure Devices Market

This Femoral Artery Closure Devices Market Report covers 100% of device types, applications, and clinical settings. The analysis evaluates over 25 device models across 5 size categories. Coverage includes procedural success metrics above 96%, complication rates below 4%, and ambulation benchmarks under 2 hours. The report analyzes 4 regions and 20+ healthcare systems. Competitive assessment includes 5 major manufacturers representing 82% of global supply. Market insights address trends, segmentation, investment activity, and innovation impacting 90% of catheterbased interventions worldwide.

Femoral Artery Closure Devices Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 1380.32 Billion in 2026
Market Size Value By	USD 2879.24 Billion by 2035
Growth Rate	CAGR of 7.7% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : 5F 6F 7F 8F Others By Application : Hospital Clinic
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample